Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Change in Accured Expenses (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of Change in Accured Expenses data on record, last reported at $2.3 million in Q3 2025.

  • For Q3 2025, Change in Accured Expenses fell 18.79% year-over-year to $2.3 million; the TTM value through Sep 2025 reached -$717000.0, down 213.27%, while the annual FY2024 figure was $1.1 million, 171.16% up from the prior year.
  • Change in Accured Expenses reached $2.3 million in Q3 2025 per ASMB's latest filing, up from $1.1 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $7.5 million in Q2 2021 and bottomed at -$8.3 million in Q1 2021.
  • Average Change in Accured Expenses over 5 years is -$114368.4, with a median of $196000.0 recorded in 2022.
  • Peak YoY movement for Change in Accured Expenses: surged 1644.74% in 2024, then crashed 488.42% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at -$344000.0 in 2021, then skyrocketed by 576.74% to $1.6 million in 2022, then tumbled by 104.15% to -$68000.0 in 2023, then surged by 713.24% to $417000.0 in 2024, then skyrocketed by 456.59% to $2.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $2.3 million in Q3 2025, $1.1 million in Q2 2025, and -$4.6 million in Q1 2025.